Pre-index antibiotic and organ-support burden flag ICU MDRO risk

This single-center matched cohort quantifies routinely available pre-index factors that stewardship pharmacists can use to flag ICU patients at higher risk of multidrug-resistant organism infection.

multidrug-resistant organismsantimicrobial stewardshipcarbapenem resistanceCRABCRECRPAintensive care unitventilator-associated pneumoniabloodstream infectionprocalcitoninpropensity score matchingrisk stratificationobservational cohort Clinical Pharmacy Practice

Background Information

MDRO risk factors in ICUs spotlight antimicrobial stewardship needs.

Multidrug-resistant organism (MDRO) infections significantly impact patient outcomes in intensive care units (ICUs), necessitating targeted prevention and stewardship efforts. MDRO infections were seen in 10.4% of ICU admissions. Factors such as severity of illness, prior antibiotic exposure, mechanical ventilation, and inflammatory markers were associated with MDRO risk. These findings can guide ICU risk stratification efforts, but further validation and evaluation of time-dependent exposures are necessary. Identifying MDRO risk factors in ICUs supports improved antimicrobial stewardship.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Ma XJ, Chen MN

Citation: Ma XJ, Chen MN Pathogen characteristics and pre-index clinical factors associated with multidrug-resistant organism infections in intensive care unit patients. Frontiers in public health. 2026;14:1821168. doi:10.3389/fpubh.2026.1821168

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →